home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 07/28/23

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today annou...
IMMP - Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,...

IMMP - Immutep Completes A$80 Million Capital Raise

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today anno...

IMMP - Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104)...
IMMP - Immutep to Participate at the Jefferies Healthcare Conference

SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO o...

IMMP - Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase II Promising efficacy in patients with a PD-L1 Combined Positive Score (CPS...

IMMP - IMMP, KPRX and HCDI among premarket losers

2023-06-02 08:11:37 ET SentinelOne ( S ) -36% after Q1 results . Kiora Pharmaceuticals ( KPRX ) -36% . Tigo Energy ( TYGO ) -16% . PagerDuty ( PD ) -16% . after Q1 results . Immutep ( IMMP ) -10% . Harbor Custom Developme...
IMMP - Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) ( Immutep or the Company ), is pleased to announce the successful completion of an institutional placement ( Placement ) and the institutional component ( Institutio...

IMMP - IMMP, GSIT and ATTO among pre-market losers

2023-05-31 08:32:12 ET Belite Bio ( BLTE ) -37% commences public offering of American Depositary Shares of $30M. Advance Auto Parts ( AAP ) -27% after Q1 earning release . Ambarella ( AMBA ) -20% after Q1 earning release . FG Financial Group (FG...

IMMP - Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study

Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat ...
Previous 10 Next 10